Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$3.13 USD
+0.05 (1.63%)
Updated Jun 5, 2024 03:57 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LSTA 3.13 +0.05(1.63%)
Will LSTA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSTA
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy
Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up
Other News for LSTA
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
Buy Rating on Lisata Therapeutics Backed by Regulatory Milestones and Promising Study Progress
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
Lisata Therapeutics receives PIP waiver from EMA for certepetide
Positive Outlook for Lisata Therapeutics as Analyst Reaffirms Buy Rating Amid Strong Financials and Promising Clinical Trials